Original Article
Efficacy and perioperative safety of FLOT regimen in neoadjuvant chemotherapy for gastric adenocarcinoma
Zhang Junli, Zhang Xijie, Liu Ying, Li Sen, Ma Pengfei, Cao Yanghui, Liu Chenyu, Li Zhenyu, Zhao Yuzhou
Published 2020-11-25
Cite as Chin J Gen Surg, 2020, 35(11): 847-851. DOI: 10.3760/cma.j.cn113855-20200607-00460
Abstract
ObjectiveTo evaluate the efficacy and perioperative safety of FLOT regimen in neoadjuvant chemotherapy for gastric adenocarcinoma.
MethodsData of 128 cases of neoadjuvant chemotherapy for gastric adenocarcinoma at the General Surgery Department of He′nan Cancer Hospital from Jan2018 to July 2019 were divided into FLOT group and SOX/XELOX group.
ResultsThe disease control rate in the FLOT group was 81%, while that in the SOX/XELOX group was only 60% (P=0.040). In terms of TRG classification and ypT staging, the proportion of TRG0 / 1 in the FLOT group was 49%, which was significantly higher than 21% in the SOX / XELOX group (P=0.001). In the FLOT group, ypT0-4 was 2, 10, 8, 17 and 6, respectively, while in the SOX/XELOX group, ypT0-4 was 1, 9, 15, 26 and 34, respectively, (P=0.022). In the FLOT group, ypTNM stages Ⅰ, Ⅱ, and Ⅲ were 11, 20, and 12, respectively, while in the SOX/XELOX group, ypTNM stages Ⅰ, Ⅱ, and Ⅲ were 12, 30, and 43, respectively (P=0.040). Complications occurred in 10 patients (23%) in the FLOT group and 18 patients (21%) in the SOX/XELOX group (P>0.05).
ConclusionsFLOT neoadjuvant chemotherapy for advanced gastric adenocarcinoma does not increase the incidence of perioperative complications while effecting tumor regression and downstaging compared to SOX/XELOX regimen.
Key words:
Stomach neoplasms; Antineoplastic combined chemotherapy protocols; Neoadjuvant therapy; Safety
Contributor Information
Zhang Junli
Department of General Surgery, Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou 450000, China
Zhang Xijie
Department of General Surgery, Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou 450000, China
Liu Ying
Depatment of Digestive Medicine, Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou 450000, China
Li Sen
Department of General Surgery, Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou 450000, China
Ma Pengfei
Department of General Surgery, Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou 450000, China
Cao Yanghui
Department of General Surgery, Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou 450000, China
Liu Chenyu
Department of General Surgery, Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou 450000, China
Li Zhenyu
Department of General Surgery, Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou 450000, China
Zhao Yuzhou
Department of General Surgery, Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou 450000, China
